Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 419

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Natural history of infantile‐onset spinal muscular atrophy

Open access
Kolb, Stephen J., Coffey, Christopher S., Yankey, Jon W., Krosschell, Kristin, Arnold, W. David, Rutkove, Seward B., Swoboda, Kathryn J., Reyna, Sandra P., Sakonju, Ai, Darras, Basil T., Shell, Richard, Kuntz, Nancy, Castro, Diana, Parsons, Julie, Connolly, Anne M., Chiriboga, Claudia A., McDonald, Craig, Burnette, W. Bryan, Werner, Klaus, Thangarajh, Mathula, Shieh, Perry B., Finanger, Erika, Cudkowicz, Merit E., McGovern, Michelle M., McNeil, D. Elizabeth, Finkel, Richard, Iannaccone, Susan T., Kaye, Edward, Kingsley, Allison, Renusch, Samantha R., McGovern, Vicki L., Wang, Xueqian, Zaworski, Phillip G., Prior, Thomas W., Burghes, Arthur H.M., Bartlett, Amy, Kissel, John T., the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators·2017·Annals of Neurology

Abstract

Objective: Infantile‐onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS‐sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post‐hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile‐onset SMA. The power and utility of NeuroNEXT to provide “real‐world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.25101

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 419

Metadata

Authors
Kolb, S. J., Coffey, C. S., Yankey, J. W., Krosschell, K., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Parsons, J., Connolly, A. M., Chiriboga, C. A., McDonald, C., Burnette, W. B., Werner, K., Thangarajh, M., Shieh, P. B., Finanger, E., Cudkowicz, M. E., McGovern, M. M., McNeil, D. E., Finkel, R., Iannaccone, S. T., Kaye, E., Kingsley, A., Renusch, S. R., McGovern, V. L., Wang, X., Zaworski, P. G., Prior, T. W., Burghes, A. H. M., Bartlett, A., Kissel, J. T., & the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators
Venue
Annals of Neurology
Publisher
Wiley
Published
2017-12
Volume
82
Issue
6
Pages
883-891
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2768938988
Cited by
419
References
38
FWCI
14.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural history of infantile‐onset spinal muscular atrophy. https://app.cochat.ai/papers/10.1002/ana.25101
The paper
Kolb, S. J., Coffey, C. S., Yankey, J. W., Krosschell, K., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Parsons, J., Connolly, A. M., Chiriboga, C. A., McDonald, C., Burnette, W. B., Werner, K., . . . the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. (2017). Natural history of infantile‐onset spinal muscular atrophy. Annals of Neurology. https://doi.org/10.1002/ana.25101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.